Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for Factor V Leiden

Journal of Reproductive Immunology

Volumn 85, Issue 2, 2010, Pages 180-185

  Manuck, Tracy ^a   Branch, D Ware ^a   Lai, Yinglei ^b   Sibai, Baha ^c   Spong, Catherine Y ^d   Wendel, George ^e   Wenstrom, Katharine ^f   Samuels, Philip ^g   Caritis, Steve N ^h   Sorokin, Yoram ⁱ   Miodovnik, Menachem ^j   O'sullivan, Mary J ^k   Conway, Deborah ^l   Wapner, Ronald J ^m  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ WAYNE STATE UNIVERSITY   (United States)

^j UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^k UNIVERSITY OF MIAMI   (United States)

^l UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^m THOMAS JEFFERSON UNIVERSITY   (United States)

more..

Author keywords

Antiphospholipid antibodies; Factor V Leiden; Preeclampsia; Small for gestational age

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREECLAMPSIA; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; SCREENING; SMALL FOR DATE INFANT;

ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; FETAL GROWTH RETARDATION; HETEROZYGOTE; HUMANS; IMMUNOGLOBULIN M; MUTATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 77953614286     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2010.03.007     Document Type: Article

References (21)

1. Battaglia F.C., Lubchenco L.O. A practical classification of newborn infants by weight and gestational age. J. Pediatr. 1967, 71:159-163.
2. Branch D.W., Andres R., Digre K.B., Rote N.S., Scott J.S. The association of antiphospholipid antibodies with severe preeclampsia. Obstet. Gynecol. 1989, 73:541-545.
3. Branch D.W., Porter T.F., Rittenhouse L., et al. Antiphospholipid antibodies in women at risk for preeclamsia. Am. J. Obstet. Gynecol. 2001, 184:825-833.
4. Branch D.W. Antiphospholipid antibodies and fetal compromise. Thromb. Res. 2004, 114:415-418.
5. Crowther M.A., Kelton J.G. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann. Intern. Med. 2003, 138:128-134.
6. Dizon-Townson D., Miller C., Sibai B., et al. The relationship of the factor V leiden mutation and pregnancy outcomes for mother and fetus. Obstet. Gynecol. 2005, 106:517-524.
7. Faden D., Tincani A., Tanzi P., et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Eur. J. Obstet. Gynecol. Reprod. Biol. 1997, 73:37-42.
8. Harris E.N., Spinnato J.A. Should anticardiolipin tests be performed in otherwise healthy pregnant women?. Am. J. Obstet. Gynecol. 1991, 165:1272-1277.
9. Jahn A., Razum O., Berle P. Routine screening for intrauterine growth retardation in Germany: low sensitivity and questionable benefit for diagnosed cases. Acta Obstet. Gynecol. Scand. 1998, 77:643-648.
10. 2-glycoprotein-I antibodies in preeclampsia. Am. J. Obstet. Gynecol. 2003, 102:294-300.
11. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome. JAMA 2006, 295:1050-1057.
12. Lockwood C.J., Romero R., Feinberg R.F., Clyne L.P., Coster B., Hobbins J.C. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am. J. Obstet. Gynecol. 1989, 161:369-373.
13. Lynch A., Marlar R., Murphy J., Davila G., Santos M., Rutledge J., Emlen W. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann. Int. Med. 1994, 120:470-475.
14. Lynch A., Byers T., Emlen W., Rynes D., Shetterly S.M., Hamman R.F. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy induced hypertension: a prospective study in low-risk pregnancy. Obstet. Gynecol. 1999, 93:193-198.
15. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., DE Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4:295-306.
16. Silver R.M., Porter T.F., Leeuween I.V., Jeng G., Scott J.R., Branch D.W. Anticardiolipin antibodies: clinical consequences of " low titers" . Obstet. Gynecol. 1996, 87:494-500.
17. Simioni P., Tormene D., Spiezia L., Tognin G., Rossetto V., Prandoni P. Inherited thrombophilia and venous thromboembolism. Semin. Thromb. Hemost. 2006, 32:700-708.
18. Tebo A.E., Jaskowski T.D., Hill H.R., Branch D.W. Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin. Exp. Immunol. 2008, 154:332-338.
19. Tsapanos V., Kanellopoulos N., Cardamakis E., et al. Anticardiolipin antibodies levels in healthy pregnant and non-pregnant women. Arch. Gynecol. Obstet. 2000, 263:111-115.
20. Vila P., Hernandez M.C., Lopez-Fernandez M.F., Batlle J. Prevalence, follow-up, and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb. Haemost. 1994, 72:209-213.
21. Yasuda M., Takakuwa K., Tokunaga A., Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet. Gynecol. 1995, 86:555-559.